

<b>Evidence gap identifier</b>	COPD2
<b>Brief title</b>	Cost-effectiveness of long-term oxygen therapy (LTOT) for adults living with chronic stable hypoxemia
<b>Report</b>	<u>Management of Chronic Obstructive Pulmonary Disease (COPD)</u>
<b>Date identified</b>	19/06/2018
<b>Identified by</b>	CICER
<b>Supported by</b>	Systematic review
<b>Population</b>	Adults living with chronic stable hypoxemia
<b>Intervention</b>	LTOT plus standard care
<b>Comparator</b>	Standard care
<b>Outcome(s)</b>	Any relevant measures of costs and benefits
<b>Setting</b>	Pulmonary rehabilitation
<b>Study design</b>	Economic evaluation studies including cost-effectiveness, cost-utility, and cost-benefit analysis), costing and comparative resource use studies
<b>Further information</b>	There was a lack of evidence regarding the cost-effectiveness of LTOT, with minimal existing studies, containing methodological and transferability issues. Consequently, cost-effectiveness analyses would be required to validate these findings in the Irish context.